Galmed Unveils Potent Three-Drug Oncology Combo and Crypto-Focused Treasury Move

Introduction

GALMED PHARMACEUTICALS LTD (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic diseases, liver disorders, and gastrointestinal oncology. As of November 17, 2025, its stock was priced at $1.43 per share, representing a 37.50% increase on a daily volume of 14,537,544 shares traded on the NASDAQ.

Corporate Structure

Galmed employs between 11 and 50 professionals with expertise in clinical development, regulatory affairs, and drug discovery. The company’s lead compound, Aramchol™, is in a Phase 3 registrational study for nonalcoholic steatohepatitis (NASH) and fibrosis. A second program, Amilo-5MER, a synthetic peptide, is currently in first-in-human trials. Galmed collaborates with academic institutions, including the Hebrew University, and industry partners such as Bayer.

Biopharmaceuticals by little plant

Developments and News

On May 22, 2025, Galmed reported its financial results for the first quarter of 2025, for the period ended March 31, 2025. Key updates included:

• Aramchol significantly enhanced the effect of Bayer’s Regorafenib in gastrointestinal cancer models.
• A signed term sheet to develop a sublingual semaglutide formulation.
• Funds raised since January 2025 totaled $6.5 million; cash balance stood at $20.1 million following a $5.0 million raise in May.

On August 28, 2025, the company released its financial results for the second quarter of 2025, for the period ended June 30, 2025. Highlights included:

• Adoption of a digital asset management strategy in August 2025, with the establishment of a “Crypto Committee” to oversee a potential allocation of up to 50% of cash reserves into digital assets.
• Termination of the exclusive license for a Self-Emulsifying Drug Delivery System; formation of a new UK-based vehicle in which Galmed may invest up to $2 million for a 20% stake.
• Cash and equivalents rose to $20.7 million as of June 30, 2025.

In a Form 6-K filing dated November 17, 2025, Galmed announced results demonstrating that a three-drug combination of Aramchol, Stivarga®, and Metformin achieved significant tumor-cell killing in in-vitro and in-vivo gastrointestinal models.

At a Special General Meeting, shareholders approved an amendment to increase authorized share capital from 50 million to 900 million ordinary shares.

Financial and Strategic Analysis

Galmed’s cash position grew from $15.9 million at December 31, 2024, to $20.1 million by May 2025, and further to $20.7 million by June 30, 2025, supported by equity raises and an at-the-market facility. The net loss for Q1 2025 was $1.1 million ($0.62 per share), compared with a $1.3 million loss in Q1 2024. In Q2 2025, the net loss increased to $2.5 million ($0.63 per share), primarily driven by increased clinical and pre-clinical expenses. Research and development expenditures remained approximately $0.6 million in Q1 2025 and rose to $1.1 million in Q2 2025; general and administrative costs decreased year-over-year in Q1 but increased in Q2 due to higher personnel expenses.

Strategically, Galmed is broadening its pipeline beyond NASH and fibrosis into gastrointestinal oncology and cardiometabolic indications. The semaglutide sublingual program and digital asset management initiative reflect diversification of both product development and treasury management.

Market Position and Industry Context

As a clinical-stage biotechnology company, Galmed operates in competitive fields addressing unmet medical needs in NASH, fibrosis, and gastrointestinal cancer. Aramchol’s Phase 3 ARMOR trial positions the company among a select group targeting metabolic liver diseases. The oncology synergy studies with Bayer’s Regorafenib and the forthcoming semaglutide sublingual candidate expand its business scope. The small company size enables agile decision-making while partnerships may enhance scientific and commercial credibility.

tl;dr

On November 17, 2025, Galmed announced preclinical data for a three-drug gastrointestinal oncology combination. Cash reserves totaled approximately $20.7 million as of June 30, 2025. The company approved an increase in authorized share capital to 900 million shares and launched a digital asset management strategy. Upcoming milestones include ongoing readouts from the Phase 3 ARMOR study and advancement of oncology and semaglutide sublingual programs.